Acting on GLP-1 and GIP receptors, retatrutide promotes delayed gastric emptying and sends hunger-reducing signals to the brain
vision changes
As outlined in , the medication isnt FDA-approved in 2026, which means theres no standard pharmacy priceonly a wide range based on access pathways, dosing, and level of medical oversight
The three receptors Retatrutide activates include GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors
Based on your health assessment, medical history, current medications, and other factors, the clinician may determine that GLP-1 medication isn't appropriate for you
He argues 'Nowhere was this truer than with antisera prepared against porcine glucagon the only type of glucagon then available to researchers wishing to prepare reagents suitable for immunoassay